drugset / Trial / NCT01972178

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

NCT01972178

Phase 2 Terminated 113 enrolled Pronova BioPharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is * To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameter from baseline after 12 weeks of treatment * To evaluate the safety of PRC-4016 as assessed by adverse events and other safety parameters

Timeline

Start
2013-11
Primary completion
2014-07
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Icosabutate Small molecule 600 mg Oral
Background Atorvastatin Small molecule
Background Pravastatin Small molecule
Background Rosuvastatin Small molecule
Background Simvastatin Small molecule

Indications